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Abstract 22 
Tumour patients are at a high risk of venous thromboembolism (VTE) and the mechanism by 23 
which this occurs may involve tumour derived microvesicles (MV).  Previously, it has been 24 
shown that tumour MV become attached to endothelial cells in static conditions. To investigate 25 
whether this process occurs under physiologically relevant flow rates, tumour MV were perfused 26 
across a microfluidic device coated with growing human umbilical endothelial cells (HUVECs).  27 
Cell lines were screened for their ability to form tumour spheroids and two cell lines, ES-2 and 28 
U87 were selected, formed spheroids were transferred to a microfluidic chip and a second 29 
endothelial cell biochip was coated with HUVECs and the two chips linked. Media was flowed 30 
through the spheroid chip to the endothelial chip and procoagulant activity (PCA) of the tumour 31 
media was determined by one-stage prothrombin time assay.  32 
Tumour MV were also quantified by flow cytometry before and after interaction with HUVECs. 33 
Confocal images showed HUVECs acquired fluorescence from MV attachment. Labelled MV were 34 
proportionally lost from MV rich media with time when flowed over HUVECs and was not 35 
observed on a control chip. The loss of MV was accompanied by a proportional reduction in PCA.  36 
Flow cytometry, confocal microscopy and live flow imagery captured under pulsatile flow 37 
confirmed an associated between tumour MV and HUVECs. Tumour MV attached to endothelial 38 
cells under physiological flow rates which may be relevant to the VTE pathways in cancer 39 
patients. 40 
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Introduction 43 
Microfluidic technology is already showing potential in areas related to medicine and medical 44 
diagnostics through the manipulation of biological samples and the use of miniaturized devices 1.  45 
Microfluidic culture systems are able to function, assess, and provide data for nanoenvironments 46 
through their ability to mimic in vivo biological systems onto closely resembling in vitro microfluidic 47 
environments 2.  Moreover, microfluidics has the ability to handle microliter volumes in 48 
microchannels of 1 μm to 1000 μm and where fluid flow is strictly laminar and concentrations of 49 
molecules can be well-controlled. Since the early 1990s, this technology has been used to for 50 
biological research methods for specific analyses such as polymerase chain reaction and DNA 51 
microarrays and also appears to be an ideal tool for the study of cancer 3.  As such microfluidics 52 
has been utilised to study tumour biopsies. 53 
Tumours are known to release subcellular extracellular vesicles (EV) composed of both larger (100-54 
1000 nm) microvesicles (MV) and nano-sized exosomes (<100nm) into the bloodstream 4, 5. MV are 55 
shed from cells via a number of pathways such as apoptosis and membrane remodelling 6, 7. MV are 56 
released into the circulation where they can then be detected in blood samples using a standardised 57 
flow cytometry technique 8. MV were originally thought to be simply inert cellular debris but they 58 
have been found to play a number of roles depending on their parent cells and the antigens they 59 
retain from the parent cells 9, 10. Target cells are modulated by MV through their capacity to facilitate 60 
cell-to-cell interactions, where proteins and mRNA are transferred to neighbouring cells, raising the 61 
expression of protein on the target cell membrane and inducing cell signalling 11, 12.  MV have been 62 
implicated in the prothrombotic state associated with cancer and Tissue Factor (TF) -bearing MV 63 
(TFMV) in particular are found in cancer patients’ plasma and have been suggested as a possible 64 
risk factor for occurrence of venous thromboembolism (VTE) 13. 65 
Many tumour cells express TF, especially cancers that originate in the epithelium and TFMV are 66 
spontaneously released into the circulation by these tumours 14, 15. TF is a trans-membrane, 47-KDa-67 
glycoprotein16 and the key activator for haemostasis, serving as the protein component of tissue 68 
thromboplastin 17. TF also play a vital role in a number of cellular processes including intracellular 69 
signalling, cell proliferation, and blood vessel development 18.  70 
TFMV are found in the blood of healthy individuals 19 as well as those with cancer, but levels tend 71 
to be higher in cancer patients and this has been recorded in a number of malignancies including 72 
breast cancer 20, colorectal cancer 21, and pancreatic cancer 22, 23. Together, these results suggest the 73 
potential of TFMV as a biomarker identifying among cancer patients those who are a high 74 
thrombosis risk 24, 25.The procoagulant potential of TFMV mostly dependent on the presence of TF 75 
which can drive coagulation26 and also anionic phospholipid expression, particularly 76 
phosphatidylserine (PS). Lacroix and Dignat-George (2012) describe MV that contain both PS and 77 
TF as particularly procoagulant 27 and a significant number of prothrombotic conditions have been 78 
reported to have elevated MV numbers in plasma 28.  79 
A number of studies have also found links between TFMV and thrombosis using in vivo mice 80 
models. One such experiment by Thomas et al. 29 involved infusion of MV derived from cancer cells 81 
that showed an accumulation at the injury site as well a reduction in tail bleeding time and the time 82 
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of arterioles and venules occlusion. The study showed that MV derived from cancer cells and 83 
carrying TF and P-selectin glycoprotein ligand 1 (PSGL-1) were active in forming an in vivo 84 
thrombus 29.  The shedding by a tumour of TF-bearing MV through leaking blood vessels in the 85 
tumour mass, tumour-induced upregulation of TF expression in monocytes and endothelial cells, 86 
and upregulation of endothelial cell TF expression by chemotherapeutic agents together lead to 87 
elevated circulating TF levels 30.  Tumours which are sensitive to chemotherapy would be more 88 
likely to cause VTE, given that such tumours are more likely to shed greater numbers of MV via 89 
apoptosis 31. Involvement of TF in tumour progression has also been demonstrated via 90 
hematogenous metastasis 32,33. In vitro data has also confirmed a role for TFMV in coagulation and 91 
thrombin-generation 34, 35 and they have been shown to promote metastasis through angiogenesis, 92 
immune suppression, cancer cell survival, and invasion 13. All of these processes require the ability 93 
to interact with the endothelium.  94 
A microfluidic device has been shown previously to be capable of extracting antigen-specific MV 95 
from biologically complex samples, such as serum and conditioned medium from cultured cells. 96 
The majority of MV isolated via this method retained their native morphology 36. Wu et al. 97 
developed a microfluidic platform that first filters red blood cells out from blood and then further 98 
analyses the remaining vesicles based on their smaller size; this way, over 99% of RBCs can be 99 
removed from the initial sample, and the exosomes with desired size were further purified with an 100 
efficiency of over 98% 37.Therefore, microfluidic devices are ideal candidates to study translation of 101 
biomarkers such as tumour MV to study clinically relevant questions. 102 
The purpose of this present work is to investigate how tumour MV are able to interact with 103 
endothelial cells in vitro utilising a microfluidic platform. Understanding more fully the 104 
mechanisms of endothelial involvement in thrombotic events may help in the development of 105 
better therapeutic solutions in cancer management. 106 
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Materials and Methods 108 
Cell lines and culture 109 
The ovarian carcinoma cell line ES2 (ATCC, UK) and glioblastoma U87 cell line (ATCC, UK were 110 
seeded at 1 x 106/ml cells into 25 cm² tissue culture flask (Sarstedt, UK) and left to adhere overnight 111 
at 37°C in a 5% CO2 incubator and maintained in McCoy's 5A media or DMEM media respectively, 112 
supplemented with 10% (v/v) Foetal Bovine Serum (FBS) and 1% (v/v) Penicillin/Streptomycin (all 113 
Lonza, UK). Spheroids were formed using ultra low adherence 96-well plates (ThermoFisher, UK) 114 
seeded with 2x105 cells and cultivated over 5-7 days prior to use. Primary Human umbilical vein 115 
endothelial cells (HUVECs; PromoCell, Heidelberg, Germany) were cultured in complete 116 
endothelial cell growth media (ECGM, PromoCell). HUVECs were seeded at 1 x 106/ml cells into 25 117 
cm² cell+ tissue culture flasks (Sarstedt) and cultured at 370C in a 5% CO2 incubator. HUVECs were 118 
utilised at passages 3-6. 119 
Procoagulant activity 120 
The procoagulant potential of cell-free supernatant and cells were measured using the semi-121 
automated Thrombotrack SOLO coagulometer. This machine works by mechanical detection of the 122 
clotting endpoint method. Samples (100μl) were placed into a cuvette containing a steel ball and 123 
25mM CaCl2 (100μl) was added; finally, 100μl of control plasma (NormTrol, Helena Biosciences, 124 
UK) was added and the time taken for clot formation (prothrombin time, PT) was automatically 125 
determined. 126 
CFSE staining protocol 127 
MV released from ES-2 and U87 tumour cells were labelled via 5(6)-carboxyfluorescein diacetate N-128 
hydroxysuccinimidyl ester (CFSE) staining of the parent cells. Harvested cells (1×10⁶ cells/ml) from 129 
ES-2 and U87 cancer cells were suspended in 1 ml PBS and incubated with CellTrace™CFSE dye 130 
(Invitrogen, UK) at 5μM as a final working concentration and incubated for 20 minutes at room 131 
temperature or 37 ᵒC in the dark. Stained cells were washed twice with PBS and seeded into a series 132 
of 25 cm² cell culture flasks in 10 ml of the appropriate medium and incubated for 24 h at 37ᵒC and 133 
5% CO₂. Unlabelled cells were used as negative control.  134 
Microfluidic chips 135 
Two chips were used for HUVECs experiments, either a μ-Slide I Luer (Ibidi, Germany) or a Vena8 136 
endothelial cell biochip (Cellix, Ireland). Slides were treated with UV irradiation for 20 minutes and 137 
coated by dispensing approximately 12 μL of type B 2% v/v gelatin (Sigma Aldrich, UK) into the 138 
channel. Control chips were also treated in the same way to account for non-specific binding. Then, 139 
the biochips were then incubated for 24 hours at 4°C. Cultured HUVECs (2000 cells) were added 140 
into each channel and the reservoirs filled with 60μL of media. The biochips were incubated in the 141 
CO₂ incubator for 24 hrs at 37ᵒC. Then, labelled/unlabelled MVs were perfused over the HUVECs 142 
for 6 hours and PCA, MV quantification and microscopy images were assessed to evaluate MV 143 
interaction with HUVECs. Control chips without HUVECs were done in parallel to the 144 
experimental setup. 145 
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A μ-slide III 3D perfusion was used to hold the spheroids then flow was applied via a syringe 146 
pump (4µL/min). A μ-Slide I Luer, which was precoated with HUVECs and was attached to the 147 
output of the μ-slide III 3D chip as shown in Figure 1a and b. Samples were then collected via the 148 
output of the μ-Slide I Luer into sterile 1.5ml polypropylene tubes. 149 
 150 
Figure 1a. Basic experimental setup showing tumour fresh media contained in syringes linked to a multiwell 151 
µ-slide III 3D chip containing either ES-2 or U87 spheroids linked through to a µ-Slide I Luer containing 152 
HUVECs and finally sample collection tubes.  The experiments were carried out in a 37°C incubator. 153 
 154 
 155 
Figure 1b. Schematic of experimental setup.  Media was flowed via either syringe pump (constant flow) or 156 
Kima pump (pulsatile flow) through a microfluidic chip containing tumour spheroids. MV are released from 157 
the spheroids into the media which is then connected to a second chip coated with HUVECs to study their 158 
interaction. 159 
Ultrafiltration 160 
CFSE labelled-MV cell free media was harvested from ES2 and U87 cells and centrifuged at 300 g at 161 
4°C for 4 minutes to remove detached cells. Supernatant (6ml) was collected and filtered through 162 
Vivaspin® 6 ml concentrators (Sartorius, UK). MV were recovered from the media concentrate and 163 
PCA was assessed. The molecular weight cut off was 100kDa; MVs were presumed not to pass 164 
through as filtrate due to their relatively large size in comparison to the cut off value. 165 
Flow cytometry 166 
CFSE Labelled MVs released from ES2 and U87 tumour cells were quantified by flow cytometry 167 
before and after being passed through the biochip. Samples (50μl) of labelled (either CFSE or anti-168 
TF: FITC (Bio-rad)) and unlabelled samples were immediately analysed by flow cytometry by 169 
adding an equal volume of Accucheck beads (Invitrogen, UK) and 150μl of 0.2μm-filtered sterile 170 
Media 
Syringe pump 
µ-slide luer 
µ-slide III 3D 
A 
B 
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PBS. Unlabelled MV samples were used as negative control. A flow cytometer (BD FACSCalibur) 171 
was setup with Megamix SSC beads (Biocytex, France) that are used to define a MV gate according 172 
to side-scatter characteristics of the beads (Fig. 2) following the manufacturer’s protocol.  173 
 174 
Figure 2. Defined MV gate based on Megamix SSc beads manufacturer protocol.  The box around the 3 175 
differentially sized Megamix SSc beads on side scatter represents the MV gate set at approximately 0.2 to 0.5 176 
µm. The lowest SSc beads are 0.16µm and do not form part of the MV gate. 177 
Microscopy 178 
The μ-Slide I Luer microfluidics biochip were coated with HUVECs cells and washed twice with 179 
PBS to investigate the immobilization of (CFSE)-labelled MVs. Labelled/unlabelled MVs of ES2 and 180 
U87 cell free medium were perfused over the HUVECs for 6 hours. Confocal microscopy was 181 
performed using a Zeiss LSM710 Laser Scanning Confocal Microscope and images acquired using 182 
ZEN software (Zeiss Group, Oberkochen, Germany).  183 
  184 
The interaction of MV on HUVECs was further studied using an automated microfluidic platform 185 
(VenaFlux and Vena8 Endothelial+ biochips; Cellix, Dublin, Ireland) in order to mimic 186 
physiological flow status. The Vena8 chip was coated with HUVECs (same conditions as previously 187 
described) and connected to a Kima pump (Cellix) which delivers pulsatile flow with shear stress at 188 
450μl/min for 6 min, followed by 5 min of absence of flow. The flow chamber was then connected to 189 
the Mirus Evo Nanopump (Cellix) and the channels were rinsed three times with 25 μl of media 190 
prior to each experiment, and MV adhesion was initiated by the addition of CFSE-labelled MV 191 
supernatant of (ES-2 and U87) and unlabelled MV as well. Interaction of MV was recorded every 192 
second under a shear stress of 1 dyne/cm2 in phase contrast and the settings were equal in all 193 
conditions (exposure time 344 ms, magnification 32×) for 5 min. 194 
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Results 195 
Procoagulant activity 196 
PCA of ES-2 and U87 cells and media were assessed via the one stage PT assay. For the same 197 
concentration of cells within the assay (3 x 105) the PT was similar between the ES2 (33.0s) and U87 198 
(32.6s).  The cell free media harvested at the same time was shown in both cells line to be 199 
procoagulant with ES-2 media supporting a PT of 76.9 ±3.4s (n=4) and U87 media was less 200 
procoagulant with a PT of 137.1 ±4.3s (n=4). Ultracentrifugation using a Vivaspin (100 kDa MWCO) 201 
was shown to remove all associated PCA of the filtrated media confirming that the PCA was MV 202 
associated whereas the concentrate diluted with fresh media to the original volume was shown to 203 
retain and slightly increase PCA (ES2; 41.4±9.2s, U87; 112.8±13.3s). 204 
TF labelling of MV and interaction with HUVECs 205 
Initially, TF labelling (anti-human TF: FITC) of MV from media of ES-2 and U87 spheroids cultured 206 
on a µ-slide 3D chip was used to quantify the interaction with HUVECs under flow and the 207 
relationship between TFMV with PCA. Over a time course of 6h TFMV linearly decreased (through 208 
1-6h) from the media collected after perfusion across HUVECs on a µ-slide luer chip when 209 
compared to a coated control chip containing no HUVECs (Fig. 3). 210 
   211 
Figure 3. TFMV of ES-2 and U87 as a percentage of baseline values (n=8) when perfused across a µ-Slide I 212 
Luer containing cultured HUVECs (red square) or a gelatin control chip (black circle) with no HUVECs 213 
present (n=4) for 6h. Error bars are SD. 214 
 215 
The loss of TFMV after perfusion across HUVEC coated slides was further investigated through 216 
analysis of the PCA associated with the media following perfusion across the 6h time frame.  A 217 
clear power relationship was observed between TFMV and PCA for both cell lines and the 218 
subsequent loss of detected TFMV over time with HUVECs perfusion resulted in a slower PCA (Fig 219 
4). Control samples of MV rich tumour media passed through gelatin coated µ-slide luer chips 220 
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showed no change in PCA across the 6h experimental window (ES-2; 224.7±4.8s, U87; 190.2±7.4s) 221 
HUVECs were analysed by flow cytometry for TF expression post-perfusion and showed a mean 222 
fluorescent ratio (fluorescent intensity TF/fluorescent intensity negative control) increase relative to 223 
control HUVECs (ratio of 1) to 2.41±0.13 for HUVECs perfused with ES-2 MV and 2.16±0.26 for 224 
HUVECs perused with U87 MV (n=4). 225 
 226 
 227 
.  228 
 229 
Figure 4. Relationship between TFMV and PCA of U87(red square, n=16) and ES-2 (blue circle, n=24) 230 
media when perfused over HUVECs for 6h. Lines of best fit are for a power relationship and R2 values range 231 
from 0.904-0.985. 232 
 233 
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CFSE Labelling and detection of tumour MV 235 
To visualise the observed interaction between MV and HUVECs under flowing conditions, ES2 and 236 
U87 (1×10⁶ cells/ml) were fluorescently labelled with CFSE and incubated for 24 h. Cell free media 237 
from each tumour cell line was then harvested and perfused over HUVECs adhered to a 238 
microfluidic chip (μ-Slide I Luer) for 6h (equating to approximately 6.7*105 total MV). PCA and MV 239 
quantification was determined before and after being perfused over HUVECs.  The MV gate was 240 
defined using Megamix SSc beads and CFSE-labelled MV could be clearly identified on a 241 
fluorescence plot in comparison to unlabelled MV (Fig. 5). Independent measurements showed a 242 
relationship between PCA and the quantity of CFSE labelled MV (Fig. 6). 243 
 244 
Figure 5. CFSE fluorescently labelled (left panel) and unlabelled (right) MV populations. The individual MV 245 
events in the lower right quadrant correspond to CFSE-labelled MV (increased FL-1 signal) which were then 246 
quantified using counting beads. 247 
  248 
Figure 6. The correlation between CFSE- labelled MV with PCA of tumour media (n=16, independent 249 
measurements)    250 
 251 
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HUVECs were detached from the μ-Slide I Luer chip at the end of the 6h period and analysed for 252 
PCA and the acquisition of fluorescent properties from the CFSE labelled MV. The PCA of HUVECs 253 
(3x105 per assay) incubated with ES2 tumour media was 149±0.5s and 127±1.2s for HUVECs 254 
incubated with U87 tumour media. The PCA of HUVECs with fresh (no TFMV) media was 255 
370±17.5s. The cells were further characterised by flow cytometry and the results showed an 256 
increased fluorescence (gained from labelled tumour MV) for HUVECs compared to the control 257 
cells (Fig. 7). The mean fluorescent ratio of HUVECs relative to control increased to 10.52±1.77 for 258 
HUVECs perfused with ES-2 CFSE labelled MV and 7.53±0.64 for HUVECs perused with U87 MV 259 
(n=3). 260 
 261 
Figure 7. Representative (n=3) histogram plot of fluorescence of HUVECs perfused with U87 or ES-2 MV 262 
rich media for 6h, compared to HUVECs perfused with control media (left peak). MV were labelled with 263 
CFSE from the parent cell. 264 
  265 
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Confocal microscopy 266 
To further define the MV interaction with HUVECs, CFSE-MV labelled were perfused over 267 
HUVECs on a μ-Slide I Luer channel for 6h then washed and analysed by confocal microscopy (Fig. 268 
8). Images obtained showed fluorescence localised at the surface of HUVECs.       269 
 270 
                                                                                                         271 
 272 
 273 
 274 
 275 
                                                                                                                        276 
 277 
 278 
 279 
 280 
Figure 8. Confocal microscopy of HUVECs incubated on a µ-Slide I Luer perfused with tumour media (ES-2 281 
top panels, U87 bottom panels) with CFSE labelled MV. The left panels correspond to the fluorescent 282 
detection channel, middle panels are brightfield detection channel and the right panels are the combined 283 
images. 284 
Automated image capture under flow 285 
The Cellix system allows for live image capture under physiological flow conditions and was 286 
utilised to further confirm that the association of tumour MV with HUVECs, observed by confocal 287 
microscopy was not due to any period of static flow between the experiment and analysis.  CFSE-288 
MV were constantly passed over a Vena8 microfluidic chip precoated with HUVECs and images 289 
captured ‘as live’ under flowing conditions. MV were again observed to associate with HUVECs 290 
(Fig. 9). 291 
 292 
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 293 
Figure 9. Still images captured from a live recording showing CFSE labelled MV aggregated on HUVECs 294 
under flow. The top panel (A-C), shows labelled ES-2 MV deposition. Image A shows HUVECs cell with 295 
unlabelled ES2-MV. Images B and C show two different MV deposition with HUVECs. Image D shows U87 296 
unlabelled-MV with HUVECs. Images E and F represents the labelled U87 MV deposition on HUVECs. 297 
 298 
Discussion 299 
In this study, we demonstrate for the first time that MV formed in vitro from tumour spheroids 300 
interact with endothelial cells under flow conditions in a dual microfluidic chip assembly. After 301 
initially adhering to the HUVEC surfaces in a static condition, TFMV were shown to associate with 302 
HUVECs under dynamic flow conditions in a time dependent manner. The correlation of loss of 303 
PCA and reduction in detected TFMV when tumour media was passed over HUVECs under flow 304 
suggests direct evidence for PCA being determined by TFMV concentration and also that TFMV are 305 
lost due to their association with the endothelial cells.  Control chips coated with gelatin but 306 
without HUVECs showed no loss of MV or PCA through the experiments therefore the observed 307 
loss can be attributed to the interaction with HUVECs. We have previously shown that PCA is 308 
linked to tumour spent media concentration 23 in a power relationship, as also observed here for 309 
MV concentration (Fig. 4). The observation that the concentration of spent tumour media 310 
concentration and quantified MV both determine PCA suggests that the MV in tumour media are 311 
responsible for the associated PCA. Fluorescent and confocal microscopy (Figs 8 & 9) clearly 312 
showed a fluorescence attributed to the presence of CFSE-labelled MV on HUVECs within the 313 
microfluidic chip after tumour MV were perfused over the cells. From both TF and CFSE analysis of 314 
HUVECs post perfusion the ES-2 MV conferred an increased PCA and showed a greater 315 
fluorescence when compared to U87 MV suggesting more MV were associated with HUVECs. ES-2 316 
MV rich media was also found to possess a greater PCA prior to incubation with HUVECs which 317 
may be indicative of a greater MV concentration. After removal of MV from the media via 318 
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ultrafiltration (Vivaspin, 100kDa) the filtrate no longer supported coagulation.  The pore size of 319 
these filtration units would allow soluble TF to pass through (47kDa), if present in a monomeric or 320 
dimeric form, and so the data suggest that the PCA associated with tumour conditioned media is 321 
MV dependent as discussed above.  322 
A possible limitation of the study would be whether the interaction with endothelial cells seen here 323 
is ubiquitous and occurs for MV derived from any cell exposed to the circulation. However, the 324 
acquisition of a more procoagulant HUVEC phenotype via the acquisition of TF expressing tumour 325 
MV as shown here would be more specific to tumour derived MV. Furthermore it has been shown 326 
that although flow cytometry is the currently the only standardised method 8 across laboratories for 327 
enumeration of MV the method has a size limitation where smaller MV cannot be detected 38. The 328 
described methodology here, using Megamix beads creates an MV size window of detection of 0.2 329 
to 0.5µm (Fig. 2). 330 
The binding of procoagulant tumour MV to endothelial cells could have relevance to the in vivo 331 
mechanism of VTE formation in cancer patients where TFMV have been proposed to be associated 332 
with a high thrombosis risk 24, 25. If tumour MV are able to bind to endothelial cells within the 333 
circulation then this could be a basis for increased procoagulant potential. Future work should 334 
focus on the exact mechanism of tumour MV binding to endothelial cells and the response of 335 
endothelial cells to the stimuli in terms of activation, apoptosis or altered cell surface marker 336 
expression. 337 
It has been proposed that MV endocytosis by endothelial cells occurs through interaction between 338 
anionic phospholipids at the MV surface and endothelial cell surface expressed αvβ3 integrin 39. 339 
This process was shown to be inhibited in the presence of annexin V and the internalisation of MV 340 
and subsequent protein digestion at the MV surface by trypsin additionally provides evidence of a 341 
phospholipid role in binding of MV to endothelial cells 39. The engulfment and recycling of MV 342 
through the Rab family of Golgi-endosomal transport network has also been demonstrated 40. 343 
Furthermore, there is evidence of TF–VIIa–protease-activated receptor (PAR) 2 signalling in 344 
thrombin generation (and activation of other trans-membrane G protein-coupled receptors) leading 345 
to transcription of prothrombotic genes, signal transduction amplification cascades and also the 346 
establishment of tumours 41, 42. PAR1 can also trans-activate PAR2, which can promote an extra 347 
thrombin generation response in the endothelium and tumour environment 43.  348 
When cells are exposed to inflammatory cytokines, leukocytes are more likely to undergo 349 
microvesiculation, and are therefore capable of the production of TFMV, which may become 350 
associated with developing thrombus via P-selectin glycoprotein ligand 1–P-selectin interactions 351 
and also may stabilise the thrombus by fibrin formation induction 44, 45. Neutrophils can also recruit 352 
TFMV 46, and the extracellular traps that they project have been demonstrated in vitro to serve as an 353 
adherence site for tumour-derived TFMV 47. This may be a significant process for localising TFMV 354 
and concentrating additional TF into the developing thrombus. There is also evidence to suggest 355 
that MV are able to transfer their procoagulant potential to other cell types, and in doing so can 356 
exacerbate endothelial activation 48 as suggested here. While TF expression can be induced in 357 
cultured endothelial cells in response to inflammatory, in vivo it is probable that the TF associated 358 
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with endothelial cells is derived from TFMV released by monocytes or tumour cells 49, 50. Moreover, 359 
the expression of TF on the endothelium in response to both monocyte-derived MVs and 360 
inflammatory mediators accompanies the concomitant translocation of phospholipids such as PS, 361 
that could enhance the binding of coagulation factors 51. The induction of endothelial cell apoptosis 362 
is related to MV generation and downregulation of TF pathway inhibitor, thrombomodulin and 363 
glycosaminoglycans such as heparan sulphate on the endothelial surface 52. The resultant 364 
impairment of activation of the protein C anticoagulant pathway and reduced antithrombin III 365 
activity may be attributed to the disrupted integrity of the endothelium. In addition, activated 366 
endothelial cells express cell surface adhesion molecules which increase platelet adhesion and 367 
attract monocytes and neutrophils, all of which might further contribute to coagulation initiation or 368 
amplification 53, 54. 369 
In summary we report a microfluidic two-chip setup which showed that tumour MV released from 370 
spheroids bind to endothelial cell under dynamic, physiologically relevant flow conditions.  371 
Conclusion 372 
Tumour derived procoagulant MV were shown to become associated with endothelial cells under 373 
flow conditions within a dual microfluidic setup. Tumour MV were shown be the cause of 374 
procoagulant activity in vitro. 375 
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